BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
BioNTech and Roche terminated a mid-stage mRNA colorectal cancer vaccine trial following a safety review. The phase 2 test was scrapped after recording more deaths than the control group.
The setback contributed to a decline in shares for Arcturus and Moderna.
Epilogue added 76d ago, after coverage quieted.
The brief
BioNTech and Genentech have officially terminated a mid-stage clinical trial for an mRNA-based cancer vaccine. According to reports from Reuters, the company halted the trial specifically targeting colorectal cancer following a safety review. Fierce Biotech reports that the phase 2 test was scrapped after records indicated that there were more deaths in the group receiving the vaccine than in the control group. This termination marks a significant cessation of the experimental effort involving these two biotechnology partners. Coverage from Bloomberg and Yahoo Finance emphasizes that the decision to scrap the trial is a blow to the broader field of cancer vaccines. Bloomberg highlights the collaborative nature of the project between BioNTech and Roche, the parent organization of Genentech.
The reports focus on the failure of the phase 2 test and the immediate nature of the termination. These outlets collectively underscore that the trial was stopped because the safety profile did not meet the necessary requirements for the study to proceed. Context for this development is provided through the market reactions reported by Seeking Alpha. The setback for BioNTech's mRNA trial has had a ripple effect on other companies working with similar technology. Seeking Alpha notes that shares of Arcturus and Moderna both declined following the news of the trial's termination. This suggests that the failure of this specific colorectal cancer vaccine is being viewed by investors as a potential indicator of challenges facing the wider mRNA cancer vaccine sector.
Moving forward, the industry will monitor how this safety review impacts other mRNA oncology pipelines. While BioNTech and Genentech have halted this specific trial, the coverage does not specify if other trials in their portfolio are affected. Observers will be watching for further data releases from BioNTech and Roche regarding the specific causes of the deaths recorded in the phase 2 test. The current focus remains on the immediate termination of the colorectal cancer study and the resulting volatility in biotech stock prices.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 77d ago.
Quick answers
Why was the BioNTech-Genentech trial stopped?
The phase 2 trial for the colorectal cancer vaccine was halted after a safety review revealed more deaths in the vaccine group compared to the control group.
Which other companies were affected by this news?
Seeking Alpha reports that shares of Moderna and Arcturus declined following the news of the BioNTech trial setback.
Who were the partners in this vaccine trial?
The trial was a collaboration between BioNTech and Genentech, with Bloomberg noting the involvement of Roche.
Coverage (5)
- Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) Seeking Alpha · 80d ago
- BioNTech to terminate mid-stage trial of mRNA cancer vaccine Yahoo Finance · 80d ago
- BioNTech, Roche Scrap Cancer Vaccine Trial in Blow to Field Bloomberg.com · 80d ago
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review Reuters · 80d ago
- BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test Fierce Biotech · 80d ago
Topics
Related trends
Moderna swings to profit as momentum for cancer vaccine builds
Moderna swings to a profit as momentum builds for its cancer vaccine, according to financial reports.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Why is colorectal cancer aggressive in younger patients? Boston researchers discover new clues
Boston researchers uncover new clues explaining why colorectal cancer behaves so aggressively in younger patients.
Cutting This One Food Could Drastically Reduce Your Colon Cancer Risk
New reports and contrasting studies are examining the link between ultra-processed foods, processed meats, and an increased risk of colon cancer.
The rise of colon cancer among young people has been a mystery. Boston experts say they now have clues.
Boston experts point to new clues regarding the rise and deadliness of colorectal cancer among younger populations.
Colorectal cancer is surging in an unexpected group
New data reveals a significant surge in colorectal cancer rates across nearly all age groups, with a sixfold increase among children in the US.